Trial Search Results

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/

A multi-part study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Pliant Therapeutics, Inc.

Collaborator: Stanford University

Stanford Investigator(s):


  • Drug: PLN-74809
  • Drug: Placebo
  • Radiation: Knottin tracer


Phase 2


Inclusion Criteria:

   - Diagnosis of IPF, within 5 years prior to Screening,

   - FVC %predicted ≥50% and ≤90%

   - DLco (hemoglobin-adjusted) ≥30%

   - Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed,if
   on a stable dose for at least 3 months

Exclusion Criteria:

   - Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents
   not approved for that indication by the FDA

   - Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC
   ratio <0.7

   - Need for continuous oxygen supplementation, defined as >15 hours/day

   - Clinical evidence of active infection, including but not limited to bronchitis,
   pneumonia, sinusitis that can affect FVC measurement or IPF progression

   - Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months
   of Screening

   - Smoking of any kind within 3 months of Screening

Ages Eligible for Study

40 Years - 80 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Joshua Mooney, MD
Not Recruiting